Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

BACKGROUND: Evidence indicates that fractional doses of yellow fever vaccine are safe and sufficiently immunogenic for use during yellow fever outbreaks. However, there are no data on the generalisability of this observation to populations living with HIV. Therefore, we aimed to evaluate the immunog...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimathi, Derick, Juan-Giner, Aitana, Orindi, Benedict, Grantz, Kyra H, Bob, Ndeye S, Cheruiyot, Stanley, Hamaluba, Mainga, Kamau, Naomi, Fall, Gamou, Dia, Moussa, Mosobo, Moses, Moki, Felix, Kiogora, Kenneth, Chirro, Oscar, Thiong'o, Alexander, Mwendwa, Jane, Guantai, Andrew, Karanja, Henry K, Gitonga, John, Mugo, Daisy, Ramko, Kelly, Faye, Ousmane, Sanders, Eduard J, Grais, Rebecca F, Bejon, Philip, Warimwe, George M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371873/
https://www.ncbi.nlm.nih.gov/pubmed/37127045
http://dx.doi.org/10.1016/S1473-3099(23)00114-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371873/
https://www.ncbi.nlm.nih.gov/pubmed/37127045
http://dx.doi.org/10.1016/S1473-3099(23)00114-7

Ejemplares similares